MiMedx to acquire Sanara MedTech for $35/share in cash and stock, ~$350M enterprise value

MIMEDX GROUP, INC.

MiMedx to acquire Sanara MedTech for $35 per share ($33 cash + 0.4735 MDXG shares), total enterprise value ~$350M.
Transaction expected to be immediately accretive to revenue growth, gross margin, and adjusted EBITDA margin; over $20M in run-rate cost synergies.
MiMedx secured $300M debt commitment from Hayfin Capital Management to finance cash consideration and refinance existing debt.
Sanara stockholders holding ~38.9% of voting power have agreed to vote in favor via voting agreement.
Closing expected late 2026/early 2027, subject to Sanara stockholder approval, HSR clearance, and other conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.